Genetic expansion of a disease protein's polyglutamine sequence beyond repeat-length thresholds in the 35-50 range is the defect underlying a series of expanded CAG repeat diseases that include Huntington's disease 1 . Amyloid-like neuronal polyQ aggregates are a pathological hallmark of these human neurodegenerative diseases 1,2 , and polyQ aggregation rates show a repeat-length dependence in vitro 3, 4 and in vivo 5 . Understanding the physical basis of polyQ aggregation may therefore be a key requirement for understanding the molecular basis of such diseases. Deducing mechanisms by which amyloid growth is initiated, however, is technically challenging and is sometimes dependent on structural context. For example, we previously reported that simple polyQ sequences with pathological repeat lengths aggregate via a nucleated growth polymerization mechanism with a critical nucleus size (n*) of 1, without passing through any nonamyloid oligomeric intermediates 6, 7 . More recently, we found that the earlier reported 8,9 transient appearance of oligomeric aggregates prior to amyloid formation in the aggregation of huntingtin (HTT) N-terminal fragments is due to the ability of the N-terminal 17-aminoacid HTT NT sequence to entirely alter the spontaneous aggregation mechanism 10 . Similar sequence context effects have been reported for several other polyQ proteins, both model sequences 11,12 and disease proteins 13, 14 , raising the issue of whether the physical behavior of simple polyQ peptides has any bearing on polyQ pathobiology.
a r t i c l e s
Genetic expansion of a disease protein's polyglutamine sequence beyond repeat-length thresholds in the 35-50 range is the defect underlying a series of expanded CAG repeat diseases that include Huntington's disease 1 . Amyloid-like neuronal polyQ aggregates are a pathological hallmark of these human neurodegenerative diseases 1, 2 , and polyQ aggregation rates show a repeat-length dependence in vitro 3, 4 and in vivo 5 . Understanding the physical basis of polyQ aggregation may therefore be a key requirement for understanding the molecular basis of such diseases. Deducing mechanisms by which amyloid growth is initiated, however, is technically challenging and is sometimes dependent on structural context. For example, we previously reported that simple polyQ sequences with pathological repeat lengths aggregate via a nucleated growth polymerization mechanism with a critical nucleus size (n*) of 1, without passing through any nonamyloid oligomeric intermediates 6, 7 . More recently, we found that the earlier reported 8, 9 transient appearance of oligomeric aggregates prior to amyloid formation in the aggregation of huntingtin (HTT) N-terminal fragments is due to the ability of the N-terminal 17-aminoacid HTT NT sequence to entirely alter the spontaneous aggregation mechanism 10 . Similar sequence context effects have been reported for several other polyQ proteins, both model sequences 11, 12 and disease proteins 13, 14 , raising the issue of whether the physical behavior of simple polyQ peptides has any bearing on polyQ pathobiology.
In this paper we describe detailed aggregation kinetics studies of several polyQ-containing sequences that clarify this and other outstanding issues of polyQ biophysical behavior and its relation to disease. We show that the spontaneous aggregation of several diseaserelated, complex polyQ sequences, in analogy to simple polyQ peptides, is controlled by monomeric nucleus formation, suggesting that results from studies of polyQ model sequences are yielding data relevant to at least some polyQ pathology. We provide a detailed reanalysis of K 2 Q 37 K 2 , and a detailed new analysis of K 2 Q 23 K 2 , both of which confirm the absence of any detectable non-amyloid intermediates in their aggregation pathways. The K 2 Q 37 K 2 analysis establishes the robustness of the log-log slope value and confirms the previously reported 6 critical nucleus size of 1. In dramatic contrast, we find the critical nucleus for K 2 Q 23 K 2 to be 4. Furthermore, by examining the intervening repeat-length polyQs, we find a very sharp transition from n* = 4 to n* = 1 over the repeat-length range Q 23 to Q 26 . The data validate the monomeric nucleation model for long polyQ sequences and suggest a common folding motif for the critical nuclei for all polyQ peptides in the Q 18 to Q 47 repeat-length range. The modest differences in nucleus size revealed in these studies project huge differences in the aggregation kinetics predicted for different repeat lengths at physiological concentrations.
RESULTS

Flanking sequence effects on polyQ aggregation kinetics
Previously, we showed that addition of a polyproline sequence to the C-terminal side of polyQ slows aggregation kinetics but does not change the nucleated growth-monomeric nucleus aggregation mechanism 15 . We also showed that placing the same polyproline sequence on the N-terminal side of polyQ changes neither aggregation rates nor mechanism 15 . In contrast, we found that the N-terminal 17 amino acids of the huntingtin protein (HTT NT ) situated directly adjacent to the polyQ sequence ( Fig. 1a, top;  Supplementary Fig. 1 ) dramatically alters the aggregation mechanism and increases the aggregation rate 10 . Hydrophobicity-reducing mutations within HTT NT , however, lead to partial to complete suppression of its rate-enhancing ability 10, 16 , suggesting that the a r t i c l e s rate-acceleration and mechanism-alteration by flanking sequences are far from universal, depending greatly on details of sequence.
To address whether polyQ flanking sequences from other expanded polyQ disease proteins might impart altered aggregation behavior on polyQ sequences, we analyzed the impact of the N terminus of the disease protein ataxin-7 (AT7) 1 on the aggregation of a Q 30 sequence. This sequence has interesting similarities and differences with respect to the HTT NT sequence of huntingtin, as brought out by an analysis (Online Methods) using the disorder predictor PONDR 17 (Fig. 1a) . As in HTT, the polyQ sequence of AT7 lies near the N terminus of the protein and is followed by a short proline-rich sequence leading into a series of predicted ordered elements. As in HTT, the 29-amino-acid N-terminal sequence of AT7 (AT7 NT ) leading into the polyQ sequence is predicted to have some tendency toward order (Fig. 1a) . However, whereas the PONDR score of HTT NT is well below the 0.5 median normally associated with a tendency toward being structured 18 , the PONDR score of AT7 NT falls above the 0.5 median, suggesting a negligible tendency toward order.
We obtained a peptide consisting of the AT7 NT sequence followed by a Q 30 K 2 sequence. In contrast to the huge rate-enhancement effect of HTT NT , we found that at comparable concentrations, AT7 NT Q 30 K 2 aggregates somewhat more slowly than K 2 Q 30 K 2 (Fig. 1b) . In addition, the aggregation kinetics of this peptide showed concentration dependence (Fig. 1c) and linear time 2 plots (Fig. 1d) whose rates, as expected for nucleated growth polymerization reactions 19 , increase with increasing starting monomer concentration (Fig. 1e) . In fact, in good agreement with values obtained previously for simple polyQ peptides 6, 7, 15, [20] [21] [22] and in contrast to values obtained for HTT NTcontaining polyQ sequences 10 , the slope of the log-log plot of time 2 slopes versus starting concentration (Fig. 1e) is 2.7 for an n* value of 0.7 ( Table 1) . Dynamic light-scattering (DLS) analysis showed no aggregate formation that was not detected by the sedimentation assay (Fig. 1f) . Electron micrographs (Fig. 2) of the products of AT7 NT Q 30 K 2 aggregation show uniform, smooth-sided fibrils of ~10-nm diameter and no discernable twist (Fig. 2a) . Overall, the kinetic aggregation behavior of AT7 NT Q 30 K 2 is more like that of simple polyQ peptides and quite different from that of peptides containing the analogous HTT NT sequence. Although HTT N-terminal fragments aggregate by means of a two-step mechanism that includes non-nucleated, energetically downhill formation of non-amyloid oligomeric intermediates 10 , the initial aggregation of AT7 NT Q 30 K 2 is nucleated, with direct formation of amyloid aggregates, in analogy to the aggregation of simple polyQ peptides. These results are consistent with previous results 10, 15 showing that not all polyQ disease-protein flanking sequences alter polyQ aggregation mechanisms and kinetics.
Even for proteins like HTT that contain a flanking sequence that modifies the mechanism, it is possible that proteolytic removal of all or part of the flanking sequence in the cell would generate a polyQ-containing fragment that shows the kinetic behavior of simple polyQ sequences. Isolated polyQ sequences are relatively resistant to proteolysis, even by the proteasome 23 . In contrast, the HTT NT sequence of HTT is sensitive to trypsin cleavage in monomeric HTT N-terminal fragments to generate a polyQ-containing fragment starting at Ser16 (ref. 10) that may be biologically relevant (see Discussion). We obtained SFQ 37 P 10 K 2 , the polyQcontaining product of trypsin cleavage of an HTT N-terminal peptide, and studied its aggregation properties. We found that, as expected, removal of the bulk of the HTT NT sequence yields a peptide with aggregation kinetics that are greatly decreased compared to those for the peptide with intact HTT NT (Fig. 3a) . The time (Fig. 3b) and time 2 (Fig. 3c) plots for the aggregation of SFQ 37 P 10 K 2 show a clear concentration dependence, as quantified by a log-log plot ( Fig. 3d) with a slope of 3.0, consistent with an n* of 1.0 (Table 1) and hence a monomeric nucleus. This slope of 3.0 is in stark contrast to analogous slopes for HTT N-terminal fragment peptides, which are in the range of 1 (ref. 10) . EM images of the SFQ 37 P 10 K 2 aggregates (Fig. 2d) more strongly resemble the products of simple polyQ aggregation (K 2 Q 37 K 2 , Fig. 2b ) than aggregated HTT N-terminal fragments a r t i c l e s (Fig. 2c) . Collectively, the data show that biologically feasible cleavage within the HTT NT sequence can produce a polyQ-containing fragment whose aggregation properties more strongly resemble those of simple polyQ sequences. Whereas flanking sequences have been described to play important modulating roles in the in vitro aggregation of some polyQ-containing proteins [10] [11] [12] [13] [14] , details of the aggregation mechanisms of most polyQ disease proteins remain uncharacterized. PONDR analyses of these sequences shows that in every case, the polyQ region of the sequence lies within extended segments that are predicted to be unstructured (Supplementary Fig. 2 ). The unstructured nature of these flanking sequences suggests that they may be more sensitive to proteolytic cleavage in the cell, and even if not cleaved, they will be less likely, because of their low propensity for order, to initiate an HTT NT -like oligomerization mechanism.
Technical aspects of polyQ aggregation studies
To establish a benchmark for the studies on short polyQ peptides to be described later, we repeated a previous analysis of the peptide K 2 Q 37 K 2 . We disaggregated the peptide by our normal protocol plus filtration through a 20-nm membrane filter 24 (Online Methods), then we incubated the peptide to monitor its aggregation. For example, a 20-nm filtered 25.5 ± 0.5 µM solution of K 2 Q 37 K 2 , showing no detectable DLS signal at t = 0, (Fig. 4a) , was incubated. After 16 h, the solution still showed no detectable aggregates by DLS (Fig. 4a) , and its concentration after 20-nm filtration was not appreciably changed (Supplementary Table 1 ). Detectable aggregation of this 25-µM solution was only observed, by the HPLC sedimentation assay, after 50 h (Fig. 4b) . The aggregation kinetics data ( Fig. 4b ) yielded linear time 2 plots (Fig. 4c) and a linear log-log rate-concentration plot ( Fig. 4d ) with a slope of 2.7 ( Table 1) , corresponding to n* = 0.7 ( Table 1) . These data were obtained using nine separate starting concentrations to yield a log-log plot with nine data points; the range of slopes obtained by calculating the slope from all possible eightmembered subsets of these data points is 2.52-2.85 ( Table 1 ). The n* obtained is identical to the value of 0.7 obtained previously using only four starting concentrations of a monomer preparation that had not been subjected to the 20-nm filtration step 6 .
Recently, experiments were conducted with the peptide K 2 Q 23 K 2 , which was disaggregated by a modification of our published protocol 25 , stored frozen at high concentration in water (pH 3), then thawed, diluted and incubated in PBS at 37 °C at 8-23 µM concentration. Monitoring the reactions by size-exclusion chromatography, the authors reported a burst of monomer loss (interpreted as aggregation), equivalent to 30% of total incubated monomer within the first hour of incubation. The authors found that for a 23-µM solution, these rapidly formed aggregates at 2 and 6 h had hydrodynamic radii of about 200 nm and masses of 47-126 × 10 6 Da, but they showed no regular secondary structure (in particular, no β-sheet) 25 . Because this report was not in agreement with our own findings on longer repeat lengths in the K 2 Q N K 2 series 6,7,20-22 , we investigated the identical K 2 Q 23 K 2 sequence in our laboratory.
We disaggregated purified K 2 Q 23 K 2 by our standard protocol [26] [27] [28] and immediately incubated the resulting peptide at 52 µM in PBS at 37 °C, monitoring the reaction by the HPLC sedimentation assay. Unexpectedly, after up to 1,400 h, no detectable aggregation occurred in this reaction (data not shown). Based on this result, we set up a repeat reaction at a much higher concentration of 215 µM, using peptide that, immediately before the initiation of incubation, had been subjected to our standard disaggregation procedure 28 and an additional 20-nm filtration (Online Methods). DLS analysis showed no detectable particles in this K 2 Q 23 K 2 solution, either at t = 0 or a r t i c l e s after 2 h incubation (Fig. 5a) . The lack of appreciable formation of aggregates was confirmed by 20-nm membrane filtration, which showed that the concentration of filterable peptide after 2 h (214.4 ± 2.0 µM) was the same, within error, as the sample before incubation (214.9 ± 2.3 µM). Together, these results indicate that aggregate formation after a 2-h incubation of this 214-µM solution could not be detected by sedimentation assay, DLS or analytical membrane filtration, even though incubated at a starting concentration almost ten times that previously reported to give 30% aggregation under similar conditions 25 .
After the second membrane filtration of the 2 h-incubated sample, we incubated the 215-µM solution for an extended period at 37 °C and monitored aggregation by the HPLC sedimentation assay and by DLS. The results (Fig. 5b) show that the earliest detectable aggregate formation by sedimentation assay was at 20-24 h, at which time 1-3% of the monomer had been lost. In general agreement with this, the earliest DLS data rising reliably above buffer background was after 20-27 h incubation (Fig. 5b) . At 27 h aggregation was at about 5% ( Fig. 5b) and consisted of a broad distribution of particles with R h values centered around 100 nm (Fig. 5c) . At 52 h about 42% of monomer had been converted into aggregate (sedimentation assay), and the intensity of the DLS autocorrelation function was high and did not reach baseline, which prevented deconvolution to obtain a size distribution (Fig. 5b) . After 52 h monomer continued to disappear from solution (Fig. 5b, gray bars) , and the DLS signal became saturated, preventing the recording of data. The sensitivity of the DLS instrument was confirmed using immunoglobulin M (IgM) (~1 × 10 6 Da) as a standard. The IgM data (Fig. 5d) show that it takes a 16-µg ml −1 solution of IgM to achieve an equal amplitude to that observed when the 215-µM solution of K 2 Q 23 K 2 was 5% aggregated (that is, approximately 32 µg ml −1 aggregates), consistent with the average aggregate at this time being roughly in the size range of IgM (1 × 10 6 Da).
The absence of non-amyloid aggregates during the lag time of aggregation was confirmed by EM analysis of the same reaction. No aggregates were observed at t = 0 (Fig. 2e) . EM images taken at 24 h show only a very sparse distribution of aggregates ( Fig. 2f,g ; see Fig. 2 legend), and these initially observed aggregates appear to be clusters of smaller versions of the later observed mature aggregates. In the following hours, aggregates remain sparsely distributed but become slightly longer (27 h , Fig. 2h) , reaching a size range entirely consistent with the DLS result on the same sample (Fig. 5c) . At later time points, where the sedimentation assay shows increased aggregation, EM grids are uniformly covered with longer fibrillar aggregates (Fig. 2i-k) . There is no apparent difference in morphology between aggregates of K 2 Q 23 K 2 ( Fig. 2k) and K 2 Q 37 K 2 (Fig. 2b) .
The sources of the discrepancies between these results for K 2 Q 23 K 2 and the previous report 25 are not clear. Possible factors include differences in the peptide sample, the disaggregation protocol, the handling of disaggregated peptides and the aggregation buffer. Another group utilizing elements of our disaggregation protocol recently interpreted AFM results as indicating formation of oligomeric, non-amyloid aggregates from simple polyQ peptides 29 . It is not clear whether the apparent omission of the high-speed centrifugation step 29 , or some other difference in material, disaggregation protocol or observation method, is responsible for the different results. Introducing the hexafluoroisopropanol-trifluoroacetic acid (HFIP-TFA) protocol a r t i c l e s proved to be a major breakthrough in our ability to work with chemically synthesized polyQ peptides, as it provided a means to initially solubilize these otherwise intractable peptides 26 . We know, however, that small amounts of small aggregates can persist after HFIP-TFA treatment, either as a residue of incomplete disaggregation or as a product of organic solvent interactions with monomers. It is thus important to monitor the progress of the HFIP-TFA disaggregation 26 ; pay attention to surface/volume ratio, nitrogen flow rate and flask shape during HFIP-TFA treatment and removal to insure that peptide is distributed in a thin film and not in a gummy puddle 28 ; use (dry) vacuum to remove all traces of the α-helix-enhancing 30 HFIP before aqueous dissolution of the peptide film 28 ; avoid exposure of the resulting dry film to moist air 28, 30 ; subject the aqueous solution of this film to high-speed centrifugation 26 and/or 20-nm filtration (Online Methods) to clear final traces of aggregates; and limit storage 28 and, especially, avoid freezing 28, 31 of the resulting disaggregated monomer solution. The technology of working with polyQ peptides continues to evolve [26] [27] [28] 31, 32 , and we hope to continue to improve and simplify these methods to make the protocol more robust and more accessible.
The above experiment demonstrated that in our hands, aggregation of K 2 Q 23 K 2 at even very high concentrations is exceedingly slow and proceeds via amyloid-like structures. Not only was the aggregation much slower (even at much higher concentration) and of a different quality than suggested by previous results 25 , but aggregation was also much slower than expected based on our previous data for the slightly longer peptide K 2 Q 28 K 2 (ref. 6 ). This unexpected result prompted us to take a closer examination of K 2 Q 23 K 2 aggregation kinetics.
Repeat-length dependence of nucleus size
Working in the concentration range 103-227 µM, we carried out a concentration-dependent aggregation kinetics analysis of K 2 Q 23 K 2 . At 103 µM, the peptide aggregated exceeding slowly for the first 120 h before engaging a rapid aggregation phase (Fig. 6a, black squares) . Consistent with a nucleated growth mechanism 33 , aggregation of the same concentration of monomer was greatly enhanced in the presence of preformed seed (Fig 6a, blue, right pointing triangles) . Also consistent with a nucleated growth mechanism 33 , aggregation was reversible and showed a robust critical concentration of 3 µM (Fig. 6b) . This is equivalent to a free energy of elongation (∆G elong ) of −7.8 kcal mol −1 , similar to the value of −8.6 kcal mol −1 previously reported for Aβ fibril formation 34 . Consistent with nucleated growth polymerization, the initial phase of the aggregation kinetics had a linear time 2 plot at each concentration tested 19 (Fig. 6c) . When these time 2 rate slopes were plotted versus starting concentration in a log-log plot (Fig. 6d) , the results from the eight data points fit a straight line, as expected 6, 19 . However, in contrast with the slope values between 2.5 and 3 described above for K 2 Q 37 K 2 ( Fig. 4d and Table 1 ) and found in every previous examination of simple polyQ sequences 6, 7, 15, [20] [21] [22] , the slope of this line was 5.9 ( Table 1) , corresponding to n* = 3.9.
Because the shortest simple polyQ peptide we have ever analyzed was a K 2 Q 28 K 2 peptide, which also had an n* of about 1 (ref. 6), the value for the Q 23 peptide indicated an abrupt change in n* over a relatively short repeat-length range. To confirm this and to determine in detail how n* changes with respect to repeat length, we studied the intervening repeat lengths as well as a peptide with a repeat length well under Q 23 . The detailed kinetics data for these studies are located in Supplementary Figure 3 , and the log-log plots are shown in Figure 7 and the slope values and fitting parameters in Table 1 .
Obtaining useful data for the peptide K 2 Q 18 K 2 required even higher concentrations (up to over 1 mM) than did the Q 23 Figure 7 Log-log plots of initial reaction rates versus initial concentration. Rate data are from time 2 plots (see Supplementary Fig. 2) . (a-e) Peptides analyzed. K 2 Q 18 K 2 (a),
a r t i c l e s (Supplementary Fig. 3a) . After analysis, n* for K 2 Q 18 K 2 was found to be in the range of 4 as well ( Fig. 7a and Table 1 ). We also examined the kinetics of peptides in the repeat-length range Q 24 -Q 27 ( Fig. 7 and Supplementary Fig. 3) . We found that, as expected based on our prior examination of K 2 Q 28 K 2 (ref. 6), the K 2 Q 27 K 2 peptide shows a monomeric aggregation nucleus (Fig. 7b and Table 1 ). The Q 26 peptide also has n* ~ 1 ( Fig. 7c and Table 1 ). In contrast, the Q 25 peptide shows a slope of 4.0 (Fig. 7e) for n* = 2.0. The slope for the K 2 Q 24 K 2 peptide is 5.3, consistent with an n* of 3.3. The meaning of n* = 3.3 is not clear. The value may indicate a unique critical nucleus size of 3, or may be an intermediate value between n* = 2 and n* = 4 owing to both dimeric and tetrameric nuclei being operational for this repeat length in this concentration range. Further analysis is required to better understand the nucleation mechanism for K 2 Q 24 K 2 . Regardless of the interpretation of the Q 24 data, it is clear there is a tight transition from a tetrameric critical nucleus through a dimeric critical nucleus to a monomeric critical nucleus, as repeat length increases from Q 23 to Q 26 ( Table 1) . The aggregated products of each of these peptides are very similar by EM (Fig. 2k-p) and FTIR ( Supplementary Fig. 4) .
Characteristics of the Q 23 aggregation nucleus
To learn more about the K 2 Q 23 K 2 nucleated growth reaction, we evaluated the second-order elongation rate constant and, from it, the nucleation equilibrium constant (Fig. 8) ; thus, as previously described for other polyQ lengths 7, 22, 28 , we conducted a seeded elongation reaction of K 2 Q 23 K 2 monomers containing a known weight concentration of previously prepared K 2 Q 23 K 2 fibrils to obtain a pseudo-first-order rate constant for the elongation reaction (Fig. 8a) . We determined the concentration of growing ends in the seed aggregate (Fig. 8b) 7, 22, 28 and used this value to calculate, from the pseudo-first-order elongation (Fig. 8a) rate constant, a second-order rate constant for elongation (k + ) of 1.24 × 10 4 M −1 sec −1 , which is almost identical to the previously reported value for a K 2 Q 47 K peptide 7 . As previously discussed 7 , such k + values fall well below the diffusion limit, possibly reflecting either the slow diffusion of the large reactants and/or the operation of a rate-limiting folding step (such as the locking phase of the dock-and-lock mechanism for fibril elongation 35 , as part of the elongation cycle). Knowledge of k n* , along with the critical assumption that the elongation rate constant for fibrils is essentially the same as for nuclei, allowed us to calculate the nucleation equilibrium constant (K n* ) for K 2 Q 23 K 2 from the expression relating the y intercept of the log-log plot (Fig. 6d) to the parameters k + and K n* :
This analysis yields a value of K n* for K 2 Q 23 K 2 of 7.6 × 10 −2 l 3 mol −3 .
Using this value, we calculate that the concentration of tetrameric nucleus in pre-equilibrium with 100 µM monomer (a typical concentration in our aggregation experiments) is 7.6 × 10 −18 M. Consistent with the slower nucleation of K 2 Q 23 K 2 , this concentration is much lower than the steady state nucleus concentration of 2.6 × 10 −13 M calculated for a 100-µM concentration of K 2 Q 47 K 2 from its previously determined K n* (ref. 7) . Such values indicate the vanishingly small levels of the critical nucleus populated at any one time during nucleated growth, and thus they illustrate the tremendous challenges in carrying out any type of structural or physical characterization of such kinetic nuclei 19 .
DISCUSSION
In the thermodynamic model for nucleated growth polymerization (Fig. 9) , the nucleus is defined as the least stable species on the aggregation pathway 19, 36 . Classically this critical nucleus (n*) is envisioned as a thermodynamically highly unfavorable multimer for which the subsequent docking of additional monomer units provides net stabilization (Fig. 9a) . In precise analogy to the multimeric nucleus, the monomeric nucleus is also thermodynamically unstable, representing a very small percentage of total monomer in solution. As with other nuclei in the formalism of the thermodynamic model, the overall efficiency of nucleation depends on both the steady-state concentration of a r t i c l e s the nucleus and the rate of its elongation 21 . In contrast with multimeric nuclei, however, the thermodynamic barrier to monomeric nucleus formation is solely dependent on the conformational dynamics within monomers 7 . We have envisioned this conformational change as an extremely unfavorable ordering, or folding, of polyQ into an elongation-competent structure that contains β-sheet elements in common with the final fibril structure (Fig. 9b) 7 . One prediction from this model is that, as repeat length gets shorter, a point might be reached where formation of such a metastable, ordered monomeric folding unit will be prohibitively unfavorable. We have been conducting studies to probe the robustness and range of the monomeric nucleation model 6, 7, [20] [21] [22] .
There are nine different expanded polyQ repeat diseases, each with a different disease protein with different sequence elements flanking the polyQ tract 1 . In some cases, an adjacent element of structure dominates the initial stages of spontaneous aggregation in polyQ disease proteins 10, 13, 14 . However, the polyQ in most polyQ disease proteins is contained within a larger disordered segment (Fig. 1a and Supplementary Fig. 2 ) that may be susceptible to intracellular proteolysis and/or may have no ability to independently aggregate; thus, in contrast to the HTT 10 and AT3 (ref. 14) sequences, the AT7 N-terminal flanking sequence AT7 NT does not appear capable of triggering aggregation or of appreciably altering the normal aggregation mechanism found for model polyQ peptides flanked by solubilizing lysine residues (Fig. 1) . In fact, even the HTT NT sequence does not entirely eliminate the previously described, normal polyQ aggregation mechanism. For example, we now know that the nucleation pathway previously described for simple polyQ sequences 6, 7, 15, [20] [21] [22] contributes to overall aggregation of HTT NTcontaining fragments (M.J., A.K. Thakur, R. Mishra, R.K. and R.W., unpublished data) and may even be dominant if the HTT NT sequence is bound to another protein 37 or is post-translationally modified 16 . Likewise, proteolytic cleavage at Lys15 within the HTT NT . We show here that the peptide produced when an HTT N-terminal fragment is cleaved at Lys15 aggregates according to the same nucleated growth polymerization mechanism, with n* = 1, as previously found for similar repeat-length versions of simple polyQ peptides (Fig. 3) ; thus, further analysis of the nucleation mechanisms operative for simple polyQ peptides is not only relevant to fundamental characteristics of polymer assembly but also to the biology of disease.
In our initial description of the classical nucleated growth polymerization behavior of simple polyQ sequences, we provided a body of data consistent with a simple, two-state transformation of monomeric coils to β-sheet-rich amyloid-like aggregates, with no detectable alternatively structured intermediate aggregates and with a surprising critical nucleus of 1 (ref. 6 ). In the analyses described here, we build on this prior work but introduce several modifications designed to provide additional confidence in the results. We introduced a 20-nm filtration step as an added measure to remove any pre-existing aggregates from starting monomer solutions, evaluated all kinetics time points in duplicate and doubled the number of concentrations evaluated in the log-log plots. As described in Results, however, none of these changes made any appreciable difference in the previously obtained n* value for K 2 Q 37 K 2 . By adding DLS measurements, time-dependent, semiquantitative EM determinations and analytical filtration analyses to test for the presence of even very small aggregates in incubated samples, we have not been able to confirm recent reports of the rapid formation of non-amyloid oligomers on incubation of simple polyQ monomers 25, 29 . In fact, instead of 30% monomer loss within 2 h reported for 8-22 µM concentrations of K 2 Q 23 K 2 (ref. 25) , we found <1% loss of monomer for a 215-µM solution of the same peptide under the same conditions ( Fig. 5 and Supplementary Table 1) .
The discovery that shorter polyQ peptides aggregate by means of the same general nucleated growth polymerization mechanism, but with larger critical nuclei, further supports our approach to data analysis 6, 19 and the previously proposed monomeric nucleation pathway 6 . It suggests that the latter is part of a continuum, linked by a common structural motif, that includes, for shorter polyQ lengths, higher-order critical nuclei in the 2-4 range. Critical nuclei in this range have been reported previously for other amyloid formation reactions [38] [39] [40] [41] . Recent studies of short polyQ peptides were interpreted in terms of a quite different aggregation mechanism mediated by the initial formation of non-amyloid oligomers 42 . These peptides, however, not only are chemically different from those described here but also were disaggregated and handled differently.
Because it is sparsely and transiently populated, it is essentially impossible-especially in a solution dominated by ground state molecules-to physically characterize the kinetic nucleus of a nucleated growth polymerization reaction 19 . Structural clues might be obtained by a number of means, however, such as molecular dynamics simulations 43, 44 , synthesis and testing of model peptides 45 or model building based on established structures of more stable intermediates or products. X-ray diffraction studies suggest that amyloid-like polyQ aggregates exist as slabs of β-sheets 46, 47 with an antiparallel chain arrangement 46 . Based on such structures, we hypothesize that the Q 23 aggregation nucleus consists of four molecules of Q 23 , each contributing one segment of extended chain, which are arranged as two stacked slabs, each slab consisting of two strands of an antiparallel sheet (Fig. 9d) .
The identification of a multimeric nucleus for K 2 Q 23 K 2 aggregation has important implications for the structure of the monomeric nucleus for longer polyQs. One model for this structure is our previously described 'folding' model 6, 7 (Fig. 9b) . However, because polyQ sequences exist in aqueous solution as compact coils 42, 48 that appear to greatly resist expansion 49 , the energetically unfavorable conformational change associated with nucleation might also be modeled as a rearrangement that transiently generates an isolated segment of solvated statistical coil (Fig. 9c) . If this statistical coil model of the monomeric nucleus (Fig. 9c) were correct, however, we would expect that Q 23 would also have an n* of 1 because solution structures with all or part of the chain in solvated, statistical coil seem likely to be more thermodynamically accessible to short polyQs than to longer polyQs 50 . Models such as that shown in Figure 9c are also inconsistent with other experimental data 22 .
In contrast, a monomeric nucleus consisting of a highly organized, folded structure (Fig. 9b) is quite consistent with our model for the tetrameric nucleus for Q 23 (Fig. 9d) . The folded monomeric nucleus might thus structurally resemble the multimeric nucleus, except that all of the β-extended chain segments would now be derived from the same polypeptide sequence, through a series of turns and/or chain reversals (Fig. 9e) . Consistent with this model, we previously reported that long, mutated polyQ peptides containing β-turn-favoring proline-glycine pairs at regular intervals also aggregate by means of a monomeric nucleus, and that substitution with β-turn-enhancing d-proline-glycine pairs further accelerates aggregation 20 . Furthermore, model building 51 and molecular dynamics simulations 52 suggest that structures like that shown in Figure 9e are feasible. Finally, it seems a r t i c l e s reasonable to conclude that the high degree of structural similarity in EMs (Fig. 2) and FTIR (Supplementary Fig. 4 ) between the Q 23 and Q 37 aggregates are ultimately derived from similarities in nucleus structure. A further extension of this logic suggests the structure shown in Figure 9f as a reasonable one for the dimeric critical nucleus implicated in the aggregation of K 2 Q 25 K 2 ( Table 1) .
Models of nucleus structure, however, are by definition speculative and can only be tested or refined indirectly, at best. Nonetheless, it is noteworthy and possibly relevant that the nucleus sizes in these experiments tend to hover around low integer values ( Table 1 ) and are largely consistent with reasonable structural models based on established principles of protein folding as well as data from structural and mutational analyses of polyQ aggregates. As critical nuclei, such structures, by definition, must be highly thermodynamically unfavorable 7 and therefore are not expected to represent the most highly populated conformation within the monomer ensemble in the kind of physical experiments described here. Such a low frequency of nucleus formation is consistent with the experimental 42, 48, 49 and computational 49, 50 demonstration of the dominant presence of condensed, disordered forms within the monomer ensemble. Because of the rarity of the nucleus in this field of condensed states, it would appear that computer simulations that mirror polyQ solution behavior may be just as hard pressed as are solution measurements to identify, characterize and quantify the extremely rare kinetic nucleus. Perhaps the best one can hope to achieve is to survey and quantify the appearance of certain structural elements in molecular dynamics simulations of polyQ peptide behavior 53 and to evaluate the energetics of hypothetical candidate nuclei 52 .
It is important to stress that the model for the monomeric nucleus shown in Figure 9e is fundamentally different from reports of organized structures of polyQ proteins inferred from physical structural data and suggested to represent toxic, misfolded forms of polyQ 54 . The calculated steady-state concentration of the monomeric nucleus in a 1-nM concentration of K 2 Q 47 K 2 monomers is in the range of 10 −18 M; the calculated concentration of the tetrameric nucleus in a 1-nM concentration of K 2 Q 23 K 2 is in the range of 10 −37 M. It is not feasible that these critical nuclei at such low concentrations might be directly toxic to cells. If aggregation critical nucleus structures are, in fact, associated with any disease-related toxicity, the effects must be indirect, bestowed by virtue of their abilities to stimulate and mediate the rapid growth of toxic polyQ aggregates.
In fact, the rather small differences in nucleus size described here have enormous consequences for projected aggregation kinetics. Extrapolation of our data (obtained through experiments in the micromolar range) into the nanomolar range of concentrations that are more likely to obtain in cells suggests a potentially huge difference in nucleation rates between Q 23 and Q 37 sequences due to the difference in their concentration dependence (Fig. 8c) . A simulation (Fig. 8d) using parameters derived from the nucleation kinetics analysis underscores the power of this apparently modest slope difference, indicating that whereas in vitro incubation at 1 nM would be expected to yield Q 37 aggregation in 10-100 years, Q 23 aggregation is expected to begin taking place only after 10-100 billion years! These extrapolations are shown only to illustrate the potential power of nucleus size to control aggregation propensity. The assumption of linearity over large concentration differences that underlie the extrapolations may well not be justified; it is possible that at some low polyQ concentration, a nucleus of different size and associated kinetics might become more favored.
The complexity of aggregation nucleation revealed here introduces important new issues for polyQ aggregation-nucleated growth, including how repeat-length effects on aggregation relate to repeat-length effects on disease risk. Although the results reveal an extremely tight transition in the relationship between repeat length and nucleus size that is reminiscent of sharp transitions in curves of disease risk and repeat length 1 , the repeat-length threshold for nucleus-size change revealed by our studies is 24-25, whereas thresholds for disease risk tend to be in the 35-45 range (note, however, the single exception of the disease spinocerebellar ataxia 6, for which the repeat-length threshold is between 18 and 21 Q) 1 . Is there a molecular basis for the difference between these analogously sharp, but non-overlapping, thresholds? The data presented here provide hope for improved understanding of the connections between the repeatlength dependence of disease risk and the repeat-length dependence of polyQ physical properties, with implications for discovering new disease mechanisms and therapeutics.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/.
